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ABSTRACT 
 
Background: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only 
one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate. 
Methods: We analysed all patients with only one stroke risk factor from the merged datasets of 
SPORTIF III and V trials. Anticoagulation control was defined according to time in therapeutic 
range (TTR). 
Results: Of the original trial cohort, 1,097 patients had only one stroke risk factor. Stroke/systemic 
thromboembolic event had an incidence of 0.9 per 100 patient-years, with an incidence of 1.6 per 
100 patient-years for all-cause death and 2.3%/patient-years for the composite outcome of 
stroke/systemic thromboembolic event/all-cause death.  There were no significant differences in 
the risk for stroke/systemic thromboembolic event between sexes, nor between the different 
stroke risk factors amongst these atrial fibrillation patients with only one stroke risk factor.   
Cox regression analysis in patients treated with warfarin only found TTR to be inversely associated 
with stroke/systemic thromboembolic event (p=0.034) and all-cause death (p=0.015).  Chronic 
heart failure was significantly associated with the outcome of all-cause death (p=0.0019) and the 
composite outcome of stroke/systemic thromboembolic event/all-cause death (p=0.021).  There 
was a significant inverse linear association between TTR and the cumulative risk for both 
stroke/systemic thromboembolic event and all-cause death (both p<0.001). 
Conclusions:   In atrial fibrillation patients with only one additional stroke risk factor (i.e. CHA2DS2-
VASc= 1 in males or 2 in females), rates of major adverse events (stroke/systemic thromboembolic 
event, mortality) were high, despite anticoagulation.  TTR in warfarin-treated patients was 
inversely associated with the occurrence of both stroke/systemic thromboembolic event and all-
cause death 
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INTRODUCTION 
Oral anticoagulant (OAC) therapy is essential for stroke prevention in patients with atrial 
fibrillation
1
. While it is accepted that there is the need to anticoagulated all atrial fibrillation 
patients with a Chronic Heart Failure-Hypertension-Age 65-74-Diabetes Mellitus-Stroke-Vascular 
Disease-Age≥75-Sex Category (CHA2DS2-VASc) score ≥2
2,3
, some debate remains whether to treat 
or not treat atrial fibrillation patients with only one additional risk factor, beyond sex (i.e. males 
with CHA2DS2-VASc= 1 or females with CHA2DS2-VASc= 2)
4
. 
 
Current European Society of Cardiology (ESC) guidelines recommend consideration of OAC 
treatment in male patients with CHA2DS2-VASc= 1, after consider bleeding risk using the 
Hypertesion-Abnormal Renal and Liver Function-Stroke-Bleeding-Labile INR-Elderly-Drugs or 
Alcohol (HAS-BLED) score (Class IIa recommendation)
3
; however, American guidelines recommend 
antiplatelet therapy or no therapy as an alternative to OAC in atrial fibrillation patients with 
CHA2DS2-VASc= 1
2
. 
 
Several large observational studies have consistently reported that even in atrial fibrillation 
patients with only one additional stroke risk factor, incidence rates for major adverse outcomes 
are high if non-anticoagulated
5–7
, up to 2.55%/year for females and 2.75%/year for male patients 
for ischaemic stroke, and even higher if systemic embolic event and all-cause death are considered 
6
. OAC reduces stroke and all cause mortality, and OAC treatment improves prognosis even in 
atrial fibrillation patients with one additional stroke risk factor
5
 with a positive net clinical benefit 
(NCB) when compared to both antiplatelet treatment or no treatment
8,9
. Conversely, other 
cohorts have suggested lower event rates in atrial fibrillation patients with only one additional risk 
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factor, with ischaemic stroke rates below 1%/year both for males and females
10
, hence 
questioning the necessity to treat such patients
11
. 
 
In this study, our objective was to describe the rates of stroke/systemic thromboembolic event, 
all-cause death and their composite outcome in a large clinical trial cohort of anticoagulated non-
valvular atrial fibrillation patients with one additional risk factor (i.e. CHA2DS2-VASc= 1 in males or 
2 in females). Second, we analysed the impact of individual stroke risk factors on outcomes. Third, 
we describe the relationship between the time in therapeutic range (TTR) and outcomes in the 
subgroup of atrial fibrillation patients with CHA2DS2-VASc= 1 in males or 2 in females, who were 
treated with warfarin. 
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METHODS 
 
For the present study, we analysed the pooled datasets from the Stroke Prevention using an Oral 
Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III and V studies
12–14
. The SPORTIF 
trials were two global multicentre phase III clinical trials, one open label (SPORTIF III) and one 
double blinded (SPORTIF V) comparing the efficacy and safety of the direct thrombin inhibitor 
ximelagatran, compared to warfarin, in preventing thromboembolic stroke in non-valvular atrial 
fibrillation patients. 
 
For this analysis, we considered all the patients with only one additional risk factor for stroke 
beyond the sex category, according to CHA2DS2-VASc score
15
; that is, male atrial fibrillation 
patients with CHA2DS2-VASc = 1 and female atrial fibrillation patients with CHA2DS2-VASc = 2. 
 
TTR was calculated, in all patients treated with warfarin, according to the standardized Rosendaal 
interpolation method
16
, by assigning an INR value to each day between two successive observed 
INR values. After that, the percentage of time that the interpolated INR remained between 2 and 3 
was used to establish the TTR value. 
 
Study Outcomes 
Outcomes considered for the present study, defined and adjudicated by an independent events 
committee according to the original SPORTIF trials, were stroke/systemic thromboembolic event, 
all-cause death and the composite outcome of stroke/systemic thromboembolic event/all-cause 
death. Stroke was defined according as the acute onset of a focal neurological deficit in any of the 
carotid, vertebral or cerebral artery distribution territories lasting>24 hours. Systemic 
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thromboembolic event was recorded for the abrupt vascular insufficiency associated with clinical 
and radiological evidence of arterial occlusion in the absence of another likely mechanism. 
Mortality was related to the reported occurrence of death by any investigator. 
 
Statistical Analysis 
All continuous variables were tested for normality. Variables with normal distribution were 
expressed as means and standard deviations (SD). Non-parametric variables were expressed as 
median and interquartile range (IQR). Categorical variables, expressed as counts and percentages, 
were analysed by chi-squared test. 
 
Survival analysis, assessed by an intention-to-treat approach, was performed according both to 
sex and risk factor; differences in survival were analysed using the log-rank test and Kaplan-Meier 
curves were drafted according to the different groups. Evaluation of clinical characteristics 
significantly associated with outcomes was explored using a Cox proportional-hazards analysis. All 
variables with a p-value <0.10 for the association in the univariate analysis, were included in the 
forward stepwise multivariate model.   
 
A regression analyses were performed between TTR and cumulative risk derived from the Cox 
multivariable models, in relation to the different outcomes. Scatterplot graphs with regression line 
were also drafted. A two-sided p value <0.05 was considered statistically significant. All analyses 
were performed using SPSS v. 22.0 (IBM, NY, USA). 
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RESULTS 
 
Among the 7,329 patients enrolled in the original SPORTIF trials, 1,097 (15.0%; median [IQR] age 
61 [56-64] years; 212 (19.3%) female) had only one additional stroke risk factor, beyond sex. Of 
these, 578 (52.7%) were assigned to warfarin, while 519 (47.3%) were assigned to ximelagatran 
arm. Baseline characteristics of this cohort are summarised in Table 1. Of the stroke risk factors, 
hypertension was the most prevalent (719 patients, 65.5%), chronic heart failure in 182 (16.6%); 
and age 65-74 years in 196 (17.9%). 
 
Study outcomes 
After a median follow-up of 566 days [IQR 495-653], stroke/systemic thromboembolic event 
occurred in 15 (1.4%), all-cause death in 28 (2.6%) and the composite outcome of stroke/systemic 
thromboembolic event/all-cause death in 40 (3.6%). Cumulative incidences in these 
anticoagulated patients were 0.9 per 100 patient-years for stroke/systemic thromboembolic 
event, 1.6 per 100 patient-years for all-cause death and 2.3% patient-years for the composite 
outcome, respectively.  In the warfarin-treated subgroup, stroke/systemic thromboembolic event 
incidence was 0.9 per 100 patient-years, 2.0 per 100 patient-years for all-cause death and 2.7 per 
100 patient-years for the composite outcome. 
 
The crude incidences of various study outcomes were summarised in Table 2.  No death events 
were reported in diabetic patients, nor any study endpoints amongst patients age 65 to 74 years.  
The highest event rate for stroke/systemic thromboembolic event was reported in diabetic 
patients, while patients with chronic heart failure reported the highest rates for all-cause death 
and the composite outcome.  
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Kaplan-Meier survival analyses found no significant difference in the risk for stroke/systemic 
thromboembolic event between male and female patients [Figure 1, Panel A] or between the 
different stroke risk factors for the whole cohort [Figure 1, Panel B].  For all-cause death, there 
was a significant difference between risk factor type for predicting events, but not for sex (Log-
Rank: 2.748, p=0.097) [Figure 1, Panel C and D]. No significant difference was found for the 
composite outcome between sex (Log-Rank: 0.519, p=0.471) or risk factor type (Log-Rank: 6.901, 
p=0.141). In the warfarin-treated subgroup, Kaplan-Meier survival analyses found that no 
significant difference for sex was evident for stroke/systemic thromboembolic event (Log-Rank: 
0.310, p=0.578), all-cause death (Log-Rank: 0.662, p=0.416) and composite outcome (Log-Rank: 
0.013, p=0.908). Similarly, no significant difference for risk factor type was evident for 
stroke/systemic thromboembolic event (Log-Rank: 1.394, p=0.845), all-cause death (Log-Rank: 
7.816, p=0.099) or composite outcome (Log-Rank: 7.540, p=0.110). 
  
Impact of individual risk factors and TTR in the warfarin subgroup 
Taking hypertension as the reference (being the most prevalent risk factor), none of the risk 
factors emerged as a significant predictor compared to the others for either stroke/systemic 
thromboembolic event or the composite outcome [Figure 2]. For all-cause death, only chronic 
heart failure emerged as significant predictor (hazard ratio: 2.68, 95% confidence interval: 1.09-
6.60; p=0.032) [Figure 2]. 
 
On multivariate Cox regression analysis performed in the warfarin-treated subgroup (Table 3), 
only TTR expressed as continuous variable was inversely associated with the occurrence of 
stroke/systemic thromboembolic event (p=0.034).  For all-cause death, there was a significant 
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relationship for chronic heart failure (p=0.019), while TTR was inversely associated (p=0.015). For 
the composite outcome, TTR was significantly associated on univariate analysis (p=0.041), but on 
multivariate analysis, only chronic heart failure was significant (p=0.021).    
 
There was a significant linear inverse association between TTR (as a continuous variable) and the 
cumulative risk for both stroke/systemic thromboembolic event and all-cause death (standardized 
beta: -0.876, p<0.001 and standardized beta: -0.512, p<0.001, respectively) [Figure 3].   
 
When considering TTR quartiles, numerically higher event rates for all the study outcomes were 
seen in the lowest TTR quartile (poor anticoagulation control) compared to the highest quartile of 
TTR [stroke/systemic thromboembolic event: 3.5% vs 0.7%; all-cause mortality: 5.6% vs 2.8%; 
composite outcome:  6.9% vs 3.5%, respectively; full data not shown].  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10 
DISCUSSION 
In this clinical trial cohort of non-valvular atrial fibrillation patients with only one additional stroke 
risk factor (i.e. CHA2DS2-VASc= 1 in males or 2 in females), rates of major adverse events 
(stroke/systemic thromboembolic event, mortality) were high despite anticoagulation.   Second, 
there was no significant difference in the risk for stroke/systemic thromboembolic event between 
males or females, nor between the different stroke risk factors amongst these patients with only 
one stroke risk factor.  Third, TTR in the subgroup of warfarin-treated patients was inversely 
associated with the occurrence of both stroke/systemic thromboembolic event and all-cause 
death. 
 
Among the several stroke risk factors considered, none emerged as a significant predictor for the 
occurrence of stroke/systemic thromboembolic event and composite outcome in this 
anticoagulated cohort. Only for the occurrence of all-cause death, chronic heart failure was found 
as a significant predictor among the other risk factors. These results strengthen the concept that 
in atrial fibrillation patients with only one additional stroke risk factor (beyond sex), the risk for 
major adverse events remains consistently higher, despite anticoagulation.  For example, Chao et 
al. reported that in untreated atrial fibrillation patients with one stroke risk factor, ischaemic 
stroke risk was 2.75% per year
6
.  In an European population, Lip et al. reported that with one 
stroke risk factor, ischaemic stroke was 1.5%/year and all-cause death was 11.3%/year in 
untreated patients
7
.  Beyond the risk of stroke, atrial fibrillation patients are exposed to significant 
higher risks for an adverse clinical outcomes, as reported in other large contemporary real world 
studies, despite high percentage of patients treated with OAC
17,18
. Whilst we tend to focus on 
stroke reduction, we should remember that OAC also significantly reduces stroke/SE (by 64%), 
ischaemic stroke (by 67%) and all-cause mortality (by 26%) compared to control or placebo
19
. 
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In the large nationwide study from Danish registries, patients with one additional risk factor 
beyond sex (i.e. CHA2DS2-VASc= 1 in males or 2 in females) had significant reduced rate of events, 
in particular all-cause death, with anticoagulation
7
. An even larger study, comprising more than 
120,000 atrial fibrillation patients, reported that the NCB of patients with one additional risk factor 
treated with warfarin was consistently positive independent of risk factor NCB weights used 
whether at 1 and 5 years follow-up
8
. The Loire Valley Atrial Fibrillation Project also showed that in 
atrial fibrillation patients with one risk factor, use of OAC was inversely associated with occurrence 
major adverse events (p=0.002 for the composite outcome of death, stroke/systemic 
thromboembolic event and p=0.01 for the secondary outcome of death, stroke/systemic 
thromboembolic event and major bleeding)
5
.  Our current study therefore underscores the 
important role of OAC in non-valvular atrial fibrillation patients with only one additional stroke 
risk, in reducing major adverse outcomes. Moreover, good quality anticoagulation (with high TTR) 
is essential, to ensure best protection from adverse outcomes in warfarin-treated patients.   
Recent data show that European guideline-adherent treatment is associated with improved 
outcomes, suggesting that the recommendation of treating atrial fibrillation patients with one 
additional stroke risk factor confers a significant clinical advantage
20
. 
 
Limitations 
The main limitation is the post-hoc nature of the present study, and the SPORTIF trials included 
atrial fibrillation patients with ≥1 risk factors, the limited number of patients and events (in 
particular for the age risk factor) limit the generalizability of our results. Furthermore, SPORTIF 
trials were highly controlled randomized controlled trials the event rates may not resemble those 
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in real world populations, given the strict control of various risk factors for the entire trial follow-
up period. 
 
In conclusion, this post-hoc analysis of a clinical trial cohort of non-valvular atrial fibrillation with 
only one additional stroke risk factor (i.e. CHA2DS2-VASc= 1 in males or 2 in females) shows that 
rates of major adverse events (stroke/systemic thromboembolic event, mortality) were high, 
despite being anticoagulated.  TTR in warfarin-treated patients was inversely associated with the 
occurrence of both stroke/systemic thromboembolic event and all-cause death. 
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Table 1: Cohort Characteristics 
 Overall Population 
n=1,097 
Age years 
Median [IQR] 
 
61 [56-64] 
Age 65-74 years 196 (17.9%) 
Gender 
Male 
Female 
 
885 (80.7%) 
212 (19.3%) 
BMI kg/cm
2
 1,093 
Median [IQR] 
 
30.1 [26.8-34.5] 
Treatment Arm 
Ximelagatran 
Warfarin 
 
519 (47.3%) 
578 (52.7%) 
Chronic Atrial Fibrillation* 925 (84.3%) 
Hypertension 719 (65.5%) 
Diabetes Mellitus 231 (21.1%) 
Creatinine Clearance ml/min 1,091 
Median [IQR] 
 
110.68 [85.29-138.58] 
Vascular Disease 397 (36.2%) 
Chronic Heart Failure 182 (16.6%) 
Clinically Relevant Bleeding 41 (3.7%) 
Prior Aspirin Use 204 (18.6%) 
Prior Vitamin K-Antagonist Use 854 (77.8%) 
TTR %* 575  
Median [IQR] 
 
67.1 [55.0-78.6] 
TTR>70%* 575  255 (44.1%) 
 
Legend: BMI= body mass index; IQR= interquartile range; TTR= time in therapeutic range; *data 
available only for patients on warfarin. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2: Study Outcomes in Relation to Individual Risk Factors 
(per 100 patient-years) Stroke/Systemic 
Thromboembolic 
Event 
All-Cause Death Composite Outcome 
Hypertension 0.9 1.4 2.1 
Diabetes Mellitus 1.4 0 1.4 
Vascular Disease 0.5 1.6 2.0 
Chronic Heart Failure 1.1 3.7 4.4 
Age 65-74 years 0 0 0 
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Table 3: Univariate and Multivariable Cox Regression Analysis for Study Outcomes in the Warfarin Treated Patients  
 Univariate Analysis Multivariable Analysis 
 HR 95% CI p HR 95% CI p 
a) Stroke/Systemic Thromboembolic Event 
Congestive Heart Failure 0.73 0.09-5.95 0.771 - - - 
Hypertension 3.72 0.46-30.27 0.219 - - - 
Age 65-74 years 0.04 0.00-81.64 0.400 - - - 
Diabetes Mellitus 0.53 0.07-4.34 0.557 - - - 
Vascular Disease 0.57 0.14-2.27 0.425 - - - 
Female Sex (vs. Male) 1.57 0.32-7.78 0.581 - - - 
TTR (per point) 0.97 0.94-1.00 0.034 0.97 0.94-1.00 0.034 
b) All-Cause Death 
Congestive Heart Failure 3.04 1.19-7.72 0.020 3.11 1.20-8.04 0.019 
Hypertension 0.96 0.38-2.45 0.936 - - - 
Age 65-74 years 0.04 0.00-4.51 0.176 - - - 
Diabetes Mellitus 1.30 0.47-3.62 0.612 - - - 
Vascular Disease 1.97 0.80-4.86 0.139 - - - 
Female Sex (vs. Male) 0.55 0.13-2.38 0.423 - - - 
TTR (per point) 0.97 0.95-0.99 0.010 0.97 0.95-0.99 0.015 
c) Composite Outcome 
Congestive Heart Failure 2.58 1.11-6.04 0.028 2.74 1.16-6.48 0.021 
Hypertension 1.11 0.48-2.61 0.803 - - - 
Age 65-74 years 0.04 0.00-2.73 0.131 - - - 
Diabetes Mellitus 0.96 0.36-2.58 0.938 - - - 
Vascular Disease 1.78 0.80-3.96 0.159 - - - 
Female Sex (vs. Male) 0.94 0.32-2.75 0.908 - - - 
TTR (per point) 0.98 0.96-1.00 0.042 - - - 
Legend:  CI= confidence interval; HR= hazard ratio; TTR= time in therapeutic rate.
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FIGURE LEGENDS 
 
Figure 1: Kaplan-Meier Curves for (i) Stroke/Systemic Thromboembolic Event in relation to A) sex; 
B) risk factors; (ii) All-Cause Death in relation to C) sex; D) risk factors. 
Legend: CHF: chronic heart failure; DM: diabetes mellitus; HTN: hypertension; VD: vascular 
disease. 
 
Figure 2:  Forest-Plot for Study Outcomes According to Every Risk Factor 
Legend: CHF= chronic heart failure; DM= diabetes mellitus; HTN= hypertension; VD= vascular 
disease. 
 
Figure 3: Scatterplot and Regression Line between TTR and Cumulative Risk 
Legend: A) Stroke/Systemic Thromboembolic Event; B) All-Cause Death. TTR= time in therapeutic 
range. 
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Clinical significance 
  
• In patients with atrial fibrillation with only one additional stroke risk factor (i.e. 
CHA2DS2-VASc= 1 in males or 2 in females), rates of major adverse events 
(stroke/systemic thromboembolic event, all-cause death) were high, despite being 
on oral anticoagulation.   
• Quality of anticoagulation control (time in therapeutic range, TTR) in warfarin-
treated patients was inversely associated with the occurrence of both 
stroke/systemic thromboembolic event and all-cause death. 
